{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:35:34Z","timestamp":1790634934994,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>KEYNOTE\u2010177 demonstrated that immunotherapy was superior to chemotherapy for microsatellite\u2010instability\u2010high\u00a0(MSI\u2010high) metastatic colorectal cancer. Colorectal cancer with peritoneal metastases (CRPM) has a poorer prognosis than other metastatic sites, with an unclear role of immunotherapy. We evaluated trends in immunotherapy use and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with CRPM and MSI testing were identified in the National Cancer Database (2016\u22122020). We evaluated immunotherapy use by year and associated patient\/hospital factors. OS was compared for immunotherapy versus chemotherapy, cytoreductive surgery (CRS), and immunotherapy plus CRS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 15\u2009322 CRPM patients, 7072 (46.2%) patients had documented MSI testing, with 819 (11.6%) MSI\u2010high. Ninety\u2010eight\u00a0MSI\u2010high patients received immunotherapy alone (12.3%), increasing from 0% in 2016\u00a0to 19.1% in 2020 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). On multivariable analysis, only higher comorbidity was associated with immunotherapy (OR: 2.83 [1.22\u22126.52]). Two\u2010year OS with immunotherapy versus chemotherapy was 64.2% versus 54.1% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). In patients receiving CRS plus systemic therapy (<jats:italic>N<\/jats:italic>\u2009=\u200996), 2\u2010year OS was 68.4%. Among patients who underwent immunotherapy and CRS versus immunotherapy alone, 2\u2010year OS was 80.0% versus 60.0% (<jats:italic>p<\/jats:italic>\u2009=\u20090.14).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Immunotherapy was associated with significantly better survival compared to chemotherapy in MSI\u2010high CRPM. Two\u2010year OS with systemic\u2009+\u2009CRS was 68.4%. Despite its role in guiding treatment, MSI testing remains low for these patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.27740","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T12:01:53Z","timestamp":1722427313000},"page":"613-621","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Improved survival with immunotherapy for microsatellite unstable colorectal cancer with peritoneal metastases"],"prefix":"10.1002","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0440-493X","authenticated-orcid":false,"given":"Rhami","family":"Khorfan","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology Loma Linda University School of Medicine Loma Linda California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-5006","authenticated-orcid":false,"given":"Shaina","family":"Sedighim","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology University of California\u2010Irvine Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Caba\u2010Molina","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology Loma Linda University School of Medicine Loma Linda California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy B.","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology University of California\u2010Irvine Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheswari","family":"Senthil","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology University of California\u2010Irvine Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael\u00a0P.","family":"O'Leary","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology Loma Linda University School of Medicine Loma Linda California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0226-5005","authenticated-orcid":false,"given":"Oliver S.","family":"Eng","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology University of California\u2010Irvine Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30500-9"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.1039"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30336-4"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.3.1.590"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604867"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25265"},{"issue":"13","key":"e_1_2_8_8_1","first-page":"3087","article-title":"Loss of DNA mismatch repair in acquired resistance to cisplatin","volume":"56","author":"Aebi S","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11176"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70558-5"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022289"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01015"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2024.01.002"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08733-x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells13030245"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.008"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000264"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000253"},{"key":"e_1_2_8_21_1","first-page":"1","article-title":"Immune\u2010based cancer treatment: addressing disparities in access and outcomes","volume":"41","author":"Osarogiagbon RU","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30599-4"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00274-1"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.27740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T06:38:02Z","timestamp":1728974282000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.27740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/jso.27740"],"URL":"https:\/\/doi.org\/10.1002\/jso.27740","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"2024-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}